Day: April 13, 2023

Bagsværd, Denmark, 13 April 2023 – Novo Nordisk today announced the sales and operating profit growth at constant exchange rates (CER) for the first three months of 2023 and that the full-year sales and operating profit outlook at CER has been raised.                           In the first three months of 2023, Novo Nordisk’s sales increased by 25% and operating profit increased by 28%, both at CER. Wholesaler inventory movements in the US positively impacted sales growth.Profit and loss (CER) First three months 2023Sales growth 25%Operating profit growth 28%The sales outlook for 2023 is raised, primarily reflecting Wegovy® prescription trends in the first quarter and higher full-year expectations for sales of Wegovy® in the US. Furthermore, a second contract manufacturer is now ready to begin production, thereby...

Figure 1: Kharmagtai copper-gold district showing currently defined mineral deposits and planned resource infill drill holes. Figure 1: Kharmagtai copper-gold district showing currently defined mineral deposits and planned resource infill drill holes.Figure 2: Three diamond drill rigs drilling at Stockwork Hill. Figure 2: Three diamond drill rigs drilling at Stockwork Hill.TORONTO, April 13, 2023 (GLOBE NEWSWIRE) — Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) is pleased to announce a 30,000-metre infill diamond drill programme to support the Pre-Feasibility Study (PFS) is well-underway at the Kharmagtai copper-gold project (Figure 1). A key objective of drilling program is to upgrade the current open-pit Mineral Resource1 areas to at least Indicated classification and to inform the geometallurgical and...

STOCKHOLM, SWEDEN April 13, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has included the first patient in the company’s clinical phase 1b/2a study of the drug candidate AC01 – a new potential treatment of heart failure. AnaCardio develops AC01, a small molecule drug candidate that mimics the mode of action of the peptide hormone ghrelin. Ghrelin treatment has been shown to have a positive effect on the heart’s contractability and increases the volume of blood ejected from the heart. The clinical study, GOAL-HF1, is randomized, double-blinded, placebo-controlled, and designed to evaluate several doses of AC01 in patients with heart failure and reduced ejection fraction (HFrEF). The goal is to evaluate the drug candidate’s safety profile, tolerability and pharmacokinetics,...

NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been dosed in Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). This Phase 1 open-label study is designed to assess the safety, tolerability, and pharmacokinetic profile of 60mg, 90mg and 120mg of PCN-101 delivered subcutaneously as compared to 60mg of PCN-101 delivered intravenously (IV). The trial will enroll approximately 16 healthy volunteers across the four cohorts and is expected to be completed in the middle of 2023. In January 2023, atai announced results from the Phase 2a proof-of-concept study evaluating a single IV administration...

Limeade app is cornerstone of new “Living Well at Tyson Foods” initiative SPRINGDALE, Ark., April 13, 2023 (GLOBE NEWSWIRE) — As part of a new initiative designed to build a healthier workforce, Tyson Foods, Inc. (NYSE: TSN) has introduced a special digital tool to help its team members improve their health and well-being. Approximately 120,000 people employed by the company in the U.S. now have access to a technology platform provided by Limeade, an immersive employee well-being innovator. The platform, which is available on a voluntary basis and can be accessed by computer or through a mobile app, delivers personalized activities and resources that support emotional, physical, financial and work well-being. The Limeade platform is the cornerstone of the new “Living Well at Tyson Foods” initiative that infuses health and...

SCOTTSDALE, Ariz., April 13, 2023 (GLOBE NEWSWIRE) — Reliance Steel & Aluminum Co. (NYSE:RS) announced today that it will report first quarter 2023 financial results for the period ended March 31, 2023, on Thursday, April 27, 2023, at 6:50 a.m. Eastern Time. Reliance management will host a conference call that same day at 11:00 a.m. Eastern Time. The call will be broadcast live over the Internet hosted on the Investors section of the Company’s website at www.rsac.com. Reliance Steel & Aluminum Co.’s First Quarter 2023 Conference Call DetailsDATE:       Thursday, April 27, 2023TIME:       8:00 a.m. Pacific Time10:00 a.m. Central Time11:00 a.m. Eastern TimeDIAL-IN:       (877) 407-0792 (U.S. and Canada)(201) 689-8263 (International)CONFERENCE ID:       13737590WEBCAST:       https://viavid.webcasts.com/starthere.jsp?ei=1607252&tp_key=a5704d3bb6           For...